Shares of ProKidney Corp. (NASDAQ:PROK – Get Rating) shot up 4.7% on Wednesday . The company traded as high as $10.31 and last traded at $10.19. 80,700 shares changed hands during trading, a decline of 57% from the average session volume of 185,697 shares. The stock had previously closed at $9.73.
ProKidney Stock Up 4.7 %
The business has a 50-day moving average of $10.90 and a two-hundred day moving average of $10.13. The firm has a market capitalization of $261.27 million and a price-to-earnings ratio of -19.60.
Institutional Investors Weigh In On ProKidney
A number of institutional investors have recently added to or reduced their stakes in PROK. Tower Research Capital LLC TRC boosted its holdings in ProKidney by 98.5% during the first quarter. Tower Research Capital LLC TRC now owns 4,456 shares of the company’s stock valued at $50,000 after purchasing an additional 2,211 shares in the last quarter. Legal & General Group Plc acquired a new stake in ProKidney during the fourth quarter valued at approximately $57,000. UBS Group AG boosted its holdings in ProKidney by 97.5% during the first quarter. UBS Group AG now owns 5,209 shares of the company’s stock valued at $59,000 after purchasing an additional 2,571 shares in the last quarter. Verition Fund Management LLC acquired a new stake in ProKidney during the third quarter valued at approximately $132,000. Finally, ExodusPoint Capital Management LP acquired a new position in shares of ProKidney in the 1st quarter worth approximately $151,000.
ProKidney Company Profile
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract.
- Get a free copy of the StockNews.com research report on ProKidney (PROK)
- 5 Best Bank ETFs to Buy Now
- How to Invest in Telehealth and Telemedicine Stocks
- Target’s Guidance Looms Over The Market
- Want Clean Energy? Siemens May Be Pointing To A Breakout
- Up Over 2,600% in 5 Years, Wall Street Still Calls Celsius a Buy
Receive News & Ratings for ProKidney Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProKidney and related companies with MarketBeat.com's FREE daily email newsletter.